METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN
The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor.
1 . A method for inducing an analgesic response to inflammatory pain without inducing overt sedation in a mammal comprising administering to the mammal an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor, which combination is effective in reducing the level of or otherwise ameliorating the sensation of pain associated with inflammatory processes.
2 . The method of claim 1 wherein the NK antagonist is an NK1 antagonist.
3 . The method of claim 2 wherein the NK1 antagonist is aprepitant.
4 . The method of claim 1 wherein the neuronal excitation inhibitor is flupirtine or a pharmaceutically acceptable salt thereof.
5 . The method of claim 1 wherein the neuronal excitation inhibitor is retigabine or a pharmaceutically acceptable salt thereof.
6 . The method of claim 1 wherein the neuronal excitation inhibitor is a potassium channel opener.
7 . The method of claim 1 wherein the neuronal excitation inhibitor is an opioid or is a pharmaceutically acceptable salt, derivate, homolog or analog thereof.
8 . The method of claim 4 wherein the neuronal excitation inhibitor is an NMDA antagonist.
9 . The method of claim 1 wherein the neuronal excitation inhibitor is modulator of TRPV1 receptor.
10 . The method of claim 4 wherein flupirtine is administered in an amount of about 0.25 mg/kg to about 20 mg/kg of body weight.
11 . The method of claim 1 wherein the mammal is human.
12 . The method of claim 1 further comprising the steps of selecting a mammal on the basis of the mammal having symptoms of inflammatory pain.
13 . A delivery system for inducing an analgesic response in a mammal having inflammatory pain said delivery system comprising combined or separate formulations of (1) an NK antagonist; (2) an neuronal excitation inhibitor; and optionally (3) one or more further active agents.
14 . The delivery system of claim 13 wherein the NK antagonist is an NK1 antagonist.
15 . The delivery system of claim 13 wherein the NK1 antagonist is aprepitant.
16 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is flupirtine or a pharmaceutically acceptable salt thereof.
17 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is retigabine or a pharmaceutically acceptable salt thereof.
18 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is a potassium channel opener.
19 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is an opioid or a pharmaceutically acceptable salt, derivative, homolog or analog thereof.
20 . The delivery system of claim 13 where in the neuronal excitation inhibitor is an NMDA antagonist.
21 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is a calcium channel antagonist.
22 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is an NSAID.
23 . The delivery system of claim 13 wherein the neuronal excitation inhibitor is a modulator of TRPV1 receptor.
24 . The delivery system of claim 16 wherein flupirtine is administered in an amount of about 0.25 mg/kg to about 20 mg/kg of body weight.
25 . A method of treating inflammatory pain associated with a disease or physiological condition in a mammal without inducing overt sedation, said method comprising administering to said mammal an effective amount of an NK antagonist and a neuronal excitation inhibitor.
26 . The method of claim 25 wherein the NK antagonist is an NK1 antagonist.
27 . The method of claim 25 wherein the NK1 antagonist is aprepitant.
28 . The method of claim 25 wherein the neuronal excitation inhibitor is flupirtine or a pharmaceutically acceptable salt thereof.
29 . The method of claim 25 wherein the neuronal excitation inhibitor is retigabine or a pharmaceutically accepted salt thereof.
30 . The method of claim 25 wherein the neuronal excitation inhibitor is a potassium channel opener.
31 . The method of claim 25 wherein the neuronal excitation inhibitor is an opioid or a pharmaceutically acceptable salt, derivative, homolog or analog thereof.
32 . The method of claim 25 where in the neuronal excitation inhibitor is an NMDA antagonist.
33 . The method of claim 25 wherein the neuronal excitation inhibitor is a calcium channel antagonist.
34 . The method of claim 25 wherein the neuronal excitation inhibitor is an NSAID.
35 . The method of claim 25 wherein the neuronal excitation inhibitor is a sodium channel blocker.
36 . The method of claim 25 wherein the neuronal excitation inhibitor is a modulator of TRPV1 receptor.
37 . The method of claim 28 wherein flupirtine is administered in an amount of about 0.25 mg/kg to about 20 mg/kg of body weight.
38 . The method of claim 25 wherein the disease is selected from acne, angina, arthritis, aspiration pneumonia, disease, empyema, gastroenteritis, inflammation, intestinal flu, NEC, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, Chronic Inflammatory Demyelinating Polyneuropathy and post-operative pain and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
39 . A system for the controlled release of active compounds selected from an NK antagonist and a neuronal excitation inhibitor or a pharmaceutically acceptable salt, derivative, homolog or analog thereof, wherein the system comprises:
(a) a deposit-core comprising an effective amount of a first active compound and having defined geometric form, and
(b) a support-platform applied to the deposit-core, wherein the support-platform contains a second active compound, and at least one compound selected from the group consisting of:
(i) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the swellable polymeric material to the gellable polymeric material is in the range 1:9 to 9:1, and
(ii) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support applied to the deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids.
40 . A system for the controlled release for an NK antagonist and a neuronal excitation inhibitor wherein the system comprises:
(a) a deposit-core comprising an effective amount of (1) an NK antagonist and (2) a neuronal excitation inhibitor form; and
(b) a support platform applied to the deposit-core, the support platform comprising at least one compound selected from the group consisting of:
(i) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the swellable polymeric material to the gellable polymeric material is in the range 1:9 to 9:1, and
(ii) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support applied to the deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids.
41 . A system for the controlled release of claim 39 wherein the support platform comprises a hydroxypropylmethyl cellulose.
42 . A system for the controlled release of claim 39 wherein the support platform comprises a plasticizer, a binder, a hydrophilic agent and a hydrophobic agent.
43 . A method of treatment of a subject said method comprising selecting a subject on the basis of symptoms of inflammatory pain and administering to said subject an NK antagonist and a neuronal excitation inhibitor wherein the treatment does not cause overt sedation.
44 . The method of claim 43 wherein the subject is a human.
45 . A system for the controlled release of claim 40 wherein the support platform comprises a hydroxypropylmethyl cellulose.
46 . A system for the controlled release of claim 40 wherein the support platform comprises a plasticizer, a binder, a hydrophilic agent and a hydrophobic agent.